UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

Genmab

G

Genmab

BiotechnologyCopenhagen, Denmark
Visit Website

About Genmab

Genmab pioneered the development of differentiated antibody therapeutics, built on proprietary technologies that have produced some of oncology's most commercially successful medicines. Founded in 1999 and headquartered in Copenhagen, Denmark, the company operates as a Nasdaq-listed biotechnology firm with a global footprint spanning research, development, and commercial operations across Europe, North America, and Asia.

The company's portfolio strategy centres on antibody innovation, underpinned by platforms including DuoBody, which enables the creation of bispecific antibodies, and HexaBody, designed to enhance immune activation. These proprietary technologies have attracted major partnership agreements with pharmaceutical companies worldwide, establishing Genmab as a technology licensor as well as a drug developer in its own right.

Genmab's most recognised contribution to oncology is daratumumab, developed in collaboration with Janssen and marketed as Darzalex, which became a standard-of-care treatment for multiple myeloma. The company has continued to build its haematology and solid tumour pipeline, with a commercial-stage portfolio that includes bispecific antibody therapies such as Epkinly (epcoritamab), co-developed with AbbVie for certain B-cell malignancies.

Listed on Nasdaq under the ticker GMAB and on Nasdaq Copenhagen, Genmab occupies a distinctive position in the biotech sector: an antibody specialist that has successfully translated platform technology into approved medicines and durable industry partnerships. Further information is available at genmab.com.

Similar Companies

More in Biotechnology

B

BeiGene

BeiGene is one of the few oncology-focused biopharmaceutical companies to have built genuinely global commercial and clinical operations from a foundation in China, becoming a Nasdaq- and Hong Kong-listed organisation with a presence spanning more than 45 countries. Founded in 2010 and headquartered in Beijing, with major operations hubs in Cambridge (Massachusetts), Basel, and across the Asia-Pacific region, the company has grown into one of the largest clinical-stage and commercial oncology enterprises in the world by pipeline breadth. Oncology Pipeline & Approved Medicines The company's most widely recognised asset is zanubrutinib, a BTK inhibitor marketed as Brukinsa, which has received regulatory approval in the United States, European Union, China, and numerous other markets for haematological malignancies including chronic lymphocytic leukaemia, Waldenström's macroglobulinaemia, and mantle cell lymphoma. Brukinsa is designed as a next-generation BTK inhibitor with a selectivity and dosing profile intended to address limitations observed in earlier compounds in its class. Beyond Brukinsa, BeiGene has built an extensive pipeline spanning solid tumours and blood cancers, with programmes targeting PD-1, TIGIT, PARP, and other validated oncology pathways. Manufacturing & Global Infrastructure BeiGene operates large-scale biologics manufacturing facilities in Guangzhou and has invested significantly in end-to-end commercial infrastructure, including its own sales force in the United States and China. The company conducts clinical trials across multiple continents, with a clinical operations footprint that places it among the more active sponsors in haematology and solid tumour research globally. It has also entered into significant collaboration agreements with major pharmaceutical partners, broadening access to its pipeline assets and reinforcing its commercial reach in competitive markets. The company's dual focus on innovation originating in China alongside regulatory approval and commercialisation in Western markets reflects a distinctive model that differentiates it from both traditional Western biopharma and purely domestic Chinese peers. BeiGene trades on Nasdaq under the ticker BGNE and on the Hong Kong Stock Exchange. Further information is available at beigene.com.

View profile
A

AN2 Therapeutics

Grounded in a proprietary boron chemistry platform, AN2 Therapeutics is a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics for rare, chronic, and serious infectious diseases. The company's approach centres on translating boron chemistry into candidates that address critical unmet needs across multiple therapy areas, targeting patients where existing treatment options remain inadequate. The development pipeline spans haematologic diseases, infectious diseases and oncology, with additional early-stage research programmes directed at oncology targets, bone disorders, and infectious disease. This breadth reflects the versatility of the underlying chemistry platform and the company's stated commitment to delivering high-impact medicines. AN2 Therapeutics is led by Co-Founder, President and Chief Executive Officer Eric Easom, who brings over 35 years of leadership experience in the biotechnology and pharmaceutical industry. A significant portion of that career, spanning more than two decades, has been focused on addressing unmet needs in infectious diseases, particularly those affecting the developing world. The leadership team also includes Michael R.K. (Dickon) Alley, Ph.D. as SVP Research Fellow and Head of Biology, Sanjay Chanda, Ph.D. as Chief Development Officer, Lucy O. Day as Chief Financial Officer, Josh Eizen as Chief Legal Officer and Chief Operating Officer, and Vince Hernandez as Senior Vice President of Research and Head of Chemistry. Further information is available at an2therapeutics.com.

View profile
A

Adcentrx Therapeutics

Founded in 2021 and headquartered in San Diego, California, Adcentrx Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer and other life-threatening diseases. The company's work centres on its proprietary i-Conjugation platform, which addresses the principal engineering challenges of ADC design, including stable conjugation chemistry, cleavable linker technology, and controlled drug-antibody ratio (DAR 8), to maximise payload delivery to solid tumour cells while limiting systemic toxicity. Clinical Pipeline Adcentrx has advanced two candidates into Phase 1a/b clinical trials. ADRX-0706 is a Nectin-4 ADC currently in Phase 1b evaluation across a range of advanced solid tumours; the US FDA has granted it Fast Track Designation for locally advanced or metastatic squamous cell cervical cancer. ADRX-0405 is a STEAP1-targeting ADC in Phase 1a evaluation for metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer; it carries FDA Orphan Drug Designation for gastric cancer and is regarded as a potential first-in-class candidate for its target. Both programmes build on the i-Conjugation platform's aim to deliver best-in-class or first-in-class ADCs with differentiated clinical profiles. Funding & Partnerships Adcentrx has raised approximately $101 million across three financing rounds, including a Series A+ of $51 million led by Eight Roads Ventures and extended with participation from Quan Capital and Partners Investment. The company has entered a multi-target antibody discovery collaboration with AvantGen to source novel antibody candidates for its ADC pipeline. Further information is available at adcentrx.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy